H.C. Wainwright analyst Andrew Fein maintained a Buy rating on Rubius Therapeutics (NASDAQ:RUBY) on Tuesday, setting a price target of $40, which is approximately 60.38% above the present share price of $24.94.
Fein expects Rubius Therapeutics to post earnings per share (EPS) of -$0.50 for the second quarter of 2021.
The current consensus among 4 TipRanks analysts is for a Moderate Buy rating of shares in Rubius Therapeutics, with an average price target of $29.
The analysts price targets range from a high of $40 to a low of $20.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $0 and a net profit of -$39.72 million. The company's market cap is $2.2 billion.
According to TipRanks.com, H.C. Wainwright analyst Andrew Fein is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 12.8% and a 46.33% success rate.
Rubius Therapeutics, Inc. engages in the development of red-cell therapeutic medicines for cancer, autoimmune diseases, hemophilia, and infectious and metabolic diseases. The company was founded by Avak Kahvejian, Jordi Mata-Fink, and Noubar Afeyan and is headquartered in Cambridge, MA.